Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Sag 10.4% in April: Crecon
June 14, 2017
- Takeda Consumer Healthcare Looks to Stable, Sustainable Growth: President
June 13, 2017
- PeptiDream Licenses Peptide Discovery Platform to Shionogi
June 13, 2017
- Mochida, Ayumi Hook Up on Sales of Enbrel, Humira Biosimilars
June 13, 2017
- Kissei Gets Japan Rights to Avacopan for Rare Kidney Diseases
June 12, 2017
- Lurasidone Beats Primary Endpoint in Bipolar I Depression: Sumitomo Dainippon
June 12, 2017
- Astellas/Pfizer Amend Xtandi Trial Protocol, Topline Data Due Out This Year
June 12, 2017
- Alcohol Dependence Med Nalmefene Delivers Positive Japan Data: Otsuka/Lundbeck
June 9, 2017
- Pediatric Ozex Generics of Takata, Meiji Now Have Same Indications as Originator
June 8, 2017
- 3 Japan Generic Majors See Decelerating Growth in FY2016: Jiho Tally
June 8, 2017
- FDA Accepts Sawai’s ANDA for Tecfidera Generic
June 8, 2017
- Daiichi Sankyo’s DS-8201 Yields 40.2% ORR in HER2-Expressing Solid Tumors: PI
June 7, 2017
- CSL Japan Chief Anticipates Annual Sales of 40 Billion Yen in Midterm Business Plan Achievable
June 7, 2017
- Pfizer Boosting Global Oncology Footprint with Diverse Portfolio: SVP
June 7, 2017
- PII Data Updated for Sumitomo Dainippon’s Napabucasin
June 6, 2017
- Details Revealed for Lenvima’s Non-Inferiority Study vs Nexavar in 1st Line HCC
June 6, 2017
- Linzess Most Heavily Promoted for GPs in Launch Month of March: Anterio
June 6, 2017
- Discontinuation of Development Continues for Novel Diabetes Drugs, Including Daiichi Sankyo’s GPR119 Agonist
June 6, 2017
- Astellas, Kyoto Univ. Launch New 3-Year Joint Project
June 5, 2017
- AbbVie to Seek Indication Expansions for Humira, Competing with Biosimilars on the Strength of Original Product’s Reliability
June 5, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…